From today's announcement. Worth watching at the very least imo as they start to secure these licensing agreements. Around 150 million shares on issue:
Under the agreement Medison is granted exclusive rights for 10 years to market, distribute and sell the OvPlex panel in Israel. The Israeli population is approximately 7.5 million people with a relatively high incidence of the disease. Compared with Australia, Israel has double the rate of incidence of ovarian cancer. Medison will gain regulatory approval and HealthLinx will then receive double-digit royalties per unit on net sales.
This follows on with the other recent positive announcement:
Under the terms of its agreement with HealthLinx, INEX will have the exclusive rights to market, sell and distribute OvPlex for a period of ten years. Singapore will serve as the platform to launch into the region including India, Malaysia, Thailand, Indonesia and Vietnam.
HTX Price at posting:
8.4¢ Sentiment: LT Buy Disclosure: Held
